PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission.

Fiche publication

Date publication

mai 2025

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CADIOT Guillaume , Dr VUITTON Lucine , Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, Abitbol V, Bouguen G, Vuitton L, Gornet JM, Montuclard C, Nancey S, Cadiot G, Wils P, Gilletta C, de Maissin A, Altwegg R, Chanteloup E, Plastaras L, Ah Soune P, Bourreille A, Stefanescu C, Seksik P, Simon M, Uzzan M, Andrau P, Rouillon C, Arondel Y, Buisson A, Peyrin-Biroulet L, Mboup B, Vicaut E, Laharie D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40398832

Résumé

Real-life data regarding Inflammatory Bowel Disease (IBD) evolution after switch from intravenous (IV-IFX) to subcutaneous infliximab (SC-IFX) is necessary. The aim of this prospective multicenter cohort study was to describe the persistence, effectiveness and tolerance of SC-IFX after switch from IV-IFX.